ArticleEJNMMI research2020
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.
Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Diagnostic accuracy of ¹⁸F-FDG PET/CT radiomics for non-invasive prediction of PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.Annals of nuclear medicine · 2026Pooled it
- Predictive value of machine learning for PD-L1 expression in NSCLC: a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.Radiology · 2026Article
- Quantitative CT analysis for predicting the PD-L1 expression in lung adenocarcinoma.Japanese journal of radiology · 2026Article
- Noninvasive Prediction of Programmed Cell Death Protein-Ligand 1 Expression in Locally Advanced Non-small Cell Lung Cancer byAnnals of surgical oncology · 2025Article
- Evaluation of PD-L1 Expression in Patients With Non-Small Cell Lung Cancer Using DCE-MRI Quantitative Analysis.The clinical respiratory journal · 2025Article
- Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic value of FDG-PET/CT findings in mucosal melanoma of the head and neck treated with carbon ion radiotherapy.Annals of nuclear medicine · 2025Article
- Relationship between PD-L1 expression and [European journal of nuclear medicine and molecular imaging · 2025Article
- Effect ofPakistan journal of medical sciences · 2025Article
- Predicting PD-L1 in Lung Adenocarcinoma UsingDiagnostics (Basel, Switzerland) · 2025Article
- Article
- Non-invasive assessment of programmed cell death ligand-1 expression usingScientific reports · 2024Article
- Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([European radiology · 2024Article
- Deep learning radiomics model based on PET/CT predicts PD-L1 expression in non-small cell lung cancer.European journal of radiology open · 2024Article
- Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions.EJNMMI physics · 2024Article
- The effect of smoking on tumor immunoediting: Friend or foe?Tobacco induced diseases · 2024Review
- Deep learning-based image analysis predicts PD-L1 status fromFrontiers in oncology · 2024Article
- [Construction of A Nomogram Prediction Model for PD-L1 Expression in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Retrospective Analysis of the Predictive Value ofDiagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundImmunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring PD-L1 expression could help to select NSCLC candidates for immunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) PET/CT could provide phenotypic information on malignant tumors. Thus, this study investigated PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in NSCLC.
methodsFDG PET/CT metabolic parameters including maximum standard uptake (SUVmax), metabolic tumor volume and total lesion glycolysis of primary lesion (MTV-P, TLG-P), and combination of primary lesion and metastases (MTV-C, TLG-C) were compared with PD-L1-positive expression in patients with NSCLC. Moreover, clinicopathological characteristics, including age, gender, smoking history, serum tumor markers, tumor location, size, TNM stage, and genetic mutation were also reviewed.
resultsAll 374 patients (215 men; 159 women; age 63 ± 9 years) included 283 adenocarcinomas (ACs) and 91 squamous cell carcinomas (SCCs). PD-L1 expression was positive in 27.8% (104/374) cases. SUVmax, TLG-P, and TLG-C of PD-L1 positivity were significantly higher than PD-L1 negativity. Moreover, PD-L1 expression was obviously correlated with man, smoking, and central NSCLC. If ACs and SCCs were separately analyzed, PD-L1 positivity in ACs and SCCs was 21.6% (61/283) and 47.5% (43/91), respectively, and only SUVmax was obviously associated with PD-L1 expression. Furthermore, multivariate analysis revealed that only SUVmax was an independent predictor of PD-L1 positive expression in overall NSCLC, AC, and SCC. Using a SUVmax cut-off value of 12.5, PD-L1 status of NSCLC was predicted by FDG PET/CT with sensitivity, specificity, and accuracy of 65.4%, 86.7%, and 80.7%, respectively.
conclusionsPD-L1 expression of NSCLC was related to SUVmax, TLG, man, smoking, and central location. However, only SUVmax was an independent predictor of PD-L1 positivity, which could help to explore the existence of immune checkpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.